Sensitivity of Five Rapid HIV Tests on Oral Fluid or Finger-Stick Whole Blood: A Real-Time Comparison in a Healthcare Setting

Juliette Pavie¹, Anne Rachline¹, Bénédicte Loze¹, Laurence Niedbalski¹, Constance Delaugerre², Eric Laforgerie³, Jean-Christophe Plantier⁴, Willy Rozenbaum¹, Sylvie Chevret⁵, Jean-Michel Molina¹, François Simon²*

¹ Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, Université Paris Diderot, Paris, France, ² Service de Microbiologie, Hôpital Saint-Louis, Université Paris Diderot, Paris, France, ³ Agence Française de Sécurité Sanitaire et des Produits de Santé, Saint Denis, France, ⁴ Laboratoire Associé du Centre National de Référence sur le VIH, CHU Charles Nicolle, Rouen, France, ⁵ Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Université Paris Diderot, Paris, France

Abstract

Background: Health authorities in several countries recently recommended the expansion of human immunodeficiency virus (HIV) antibody testing, including the use of rapid tests. Several HIV rapid tests are now licensed in Europe but their sensitivity on total blood and/or oral fluid in routine healthcare settings is not known.

Methods and Findings: 200 adults with documented HIV-1 (n = 194) or HIV-2 infection (n = 6) were prospectively screened with five HIV rapid tests using either oral fluid (OF) or finger-stick whole blood (FSB). The OraQuick Advance rapid HIV1/2 was first applied to OF and then to FSB, while the other tests were applied to FSB, in the following order: Vikia HIV 1/2, Determine HIV 1–2, Determine HIV-1/2 Ag/Ab Combo and INSTI HIV-1/HIV-2. Tests negative on FSB were repeated on paired serum samples. Twenty randomly selected HIV-seronegative subjects served as controls, and the results were read blindly. Most patients had HIV-1 subtype B infection (63.3%) and most were on antiretroviral therapy (68.5%). Sensitivity was 86.5%, 94.5%, 98.5%, 94.9%, 95.8% and 99% respectively, with OraQuick OF, OraQuick FSB, Vikia, Determine, Determine Ag/Ab Combo and INSTI (p<0.0001). OraQuick was less sensitive on OF than on FSB (p = 0.008). Among the six patients with three or more negative tests, two had recent HIV infection and four patients on antiretroviral therapy had undetectable plasma viral load. When patients positive in all the tests were compared with patients who had at least one negative test, only a plasma HIV RNA level <200 cp/ml was significantly associated with a false-negative result (p = 0.009). When the 33 rapid tests negative on FSB were repeated on serum, all but six (5 negative with OraQuick, 1 with INSTI) were positive. The sensitivity of OraQuick, Determine and Determine Ag/Ab Combo was significantly better on serum than on FSB (97.5%, p = 0.04; 100%, p = 0.004; and 100%, p = 0.02, respectively).

Conclusion: When evaluated in a healthcare setting, rapid HIV tests were less sensitive on oral fluid than on finger-stick whole blood and less sensitive on finger-stick whole blood than on serum.

Citation: Pavie J, Rachline A, Loze B, Niedbalski L, Delaugerre C, et al. (2010) Sensitivity of Five Rapid HIV Tests on Oral Fluid or Finger-Stick Whole Blood: A Real-Time Comparison in a Healthcare Setting. PLoS ONE 5(7): e11581. doi:10.1371/journal.pone.0011581

Editor: Nitika Pant Pai, McGill University Health Center, Canada

Received January 13, 2010; Accepted May 27, 2010; Published July 19, 2010

Copyright: © 2010 Pavie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The official national agency, “Agence Française pour la Sécurité Sanitaire et les Produits Sanguins” (AFSSAPS), funded this study by buying all the tests and reagents and supporting the management. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript. E. Laforgerie, coauthor from Afssaps, participated in the design of the study.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: francois.simon@sls.aphp.fr

Introduction

Late diagnosis of human immunodeficiency virus (HIV) infection, resulting in delayed patient management, is associated with poorer survival [1]. About one-third of new diagnoses in industrialized countries are made when the patient is already severely immunosuppressed [2,3], while in developing countries more than 80% of patients are diagnosed at an advanced clinical stage [4,5]. In the United States, the Centers for Diseases Control and Prevention have recommended extending HIV antibody testing to people aged 13–64 years [6]. Such a program would be implemented in a variety of healthcare settings, such as hospital emergency departments, and could involve disposable rapid HIV diagnostic tests, the patient receiving the necessary information at the same site [6]. Such HIV rapid tests use finger-stick capillary whole blood (FSB) or oral fluid (OF), thus avoiding the need for venous blood sampling and centrifugation.

Medical laboratories have been using these rapid tests for more than two decades to test serum and plasma, particularly in developing countries and for emergency diagnosis [7]. They are simple to use but lack sensitivity relative to reference enzyme immunoassays (ELA), particularly during primary HIV infection and infection by variant strains [8].

In the EU, these tests must first undergo validation studies of sensitivity and specificity against panels of frozen sera or plasma
collected during primary infection and covering the principal HIV variants, previously tested with reference EIA and Western blot methods [9,10]. Sensitivity testing of rapid tests on whole blood and oral fluid is hindered by the need to test fresh samples and by the lack of a reference panel. No real-time comparisons of such HIV tests are available. Following recent French recommendations to extend HIV testing [11], including the use of rapid testing when necessary, the French agency for health product safety (Afssaps) mandated us to carry out a real-time comparison of the sensitivity of the five approved rapid tests on samples from patients with documented HIV infection.

Materials and Methods

Two hundred consecutive adults with documented HIV infection and 20 HIV-seronegative volunteers, included to permit blinded test reading, were prospectively recruited in our outpatient clinic in Saint Louis Hospital, Paris, France, from December 2008 to February 2009, with their written informed consent. The study was approved by the Paris-Saint-Louis ethics committee and the Afssaps scientific board.

HIV-1 or HIV-2 infection had been confirmed by western blot positivity. (Biorad, New Lenox blot, Paris, France). The patients’ characteristics (age, sex, CDC stage, geographic origin, HBV and HCV serostatus, antiretroviral therapy, date of HIV infection, CD4 cell count) and the HIV-1 subtype were obtained from our computerized database. Plasma viral load was determined by using the Cobas TaqMan® (Roche V1.0, Meylan, France) or Abbott RealTime method (Abbott Molecular, Rungis, France), and the viral genotypic was determined in patients infected with HIV-1 group M by polymerase gene sequencing (ViroSeq®, Celera-Abbotti). When viral load was undetectable or the patient was infected by a variant, serotyping was used to differentiate between subtype B and non B anti-V3 antibodies, and between anti-HIV-2 and anti-HIV-1 group O antibodies [11].

The five rapid HIV tests approved in Europe for use on FSB or OF were performed in the following order on samples from each subject: OraQuick Advance Rapid HIV 1/2 antibody test (Orasure/Orgentec) was performed first on oral fluid (OF) and then on finger-stick whole blood (FSB), followed by the other four tests on FSB: Vika HIV 1/2® (bioMérieux), Determine HIV 1–2® (Unipath, Inverness), Determine® HIV-1/2 Ag/Ab Combo® (Determine 4G for 4th generation; Unipath, Inverness) and INSTI HIV-1/HIV-2® (Biotylol, Nephrotek). The particularity of the Determine® HIV-1/2 Ag/Ab Combo® test is that it detects both P24 antigen and anti-HIV antibodies and can therefore potentially reduce the window of seronegativity during primary infection [14]. The same batch of tests was used throughout the study. The characteristics of the rapid tests are summarized in Table 1.

The tests were done by two physicians and two technicians specially trained for the study, in keeping with the manufacturers’ recommendations. Oral fluid was obtained with a swab, between the upper and lower teeth and gums, following the manufacturers’ instructions. Finger-stick whole blood was obtained with a microlancet after hand warming. In case of insufficient sample volume, patients underwent a second finger-stick. Blood was collected with a capillary tube and immediately deposited on the different test strips, as recommended. After 20 minutes (except for the INSTI test, which is read immediately), all the tests were read by a single investigator, different from the one who performed the tests. Consequently, the reader was unaware of the subjects’ HIV serostatus between HIV-infected patients and healthy volunteers.

Venous blood was drawn at the same time and serum was isolated by centrifugation (10 min, 3000 g) and stored at −20°C until use. The results were recorded as positive, weakly positive (faint band), negative or invalid (non reactive internal control). In case of false-negative and/or invalid results, the patient’s serum sample was thawed and retested with the corresponding falsely negative or invalid rapid test(s) and EIA. A fourth-generation EIA, the Architect® i2000SR Abbott HIV1/2 assay was considered the gold standard because of its high sensitivity for early seroconversion [14]. Architect® i2000SR assays were performed on stored frozen samples. P24 HIV-1 antigen, when present, was quantified with the Vidas HIV-1 p24 Antigen assay (bioMérieux, Marcy l’Etoile, France).

Statistical analysis

The sensitivity of the different tests was defined as the number of positive and weakly positive tests divided by the number of valid tests. Sensitivity on the 6 different tests was compared using a logistic regression model using generalized estimating equations (GEEs) approach to take into account correlated data [15]. The

### Table 1. Technical characteristic of EU-approved HIV screening rapid tests for use on whole blood and/or oral fluid.

| Test                        | Manufacturer              | Principle and antigens coated on membrane solid phase                                                                 | Binding revelation reagents                                                                 | Procedural Control coated on solid phase                                                                 | Volume Time for reading |
|-----------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------|
| Oraquick ADVANCE            | Orasure technologies (USA) | Immunochromatography HIV1 group M – group O (gp41) and HIV2 (gp36) synthetic peptides                               | Protein A labelled with reddish purple                                                      | Goat anti human Ig G                                                                                     | 5 µL blood oral fluid cravicular collection 20–40 mn |
| Vika HIV 1/2                | bioMérieux (France)       | Immunochromatography HIV1 group M - group O (gp41) and HIV2 (gp36) synthetic peptides                               | Antigens linked to blue colored microspheres                                                  | Colored bovine serum albumin                                                                            | 75 µL 20–30 mn             |
| Determine HIV 1–2           | Organics Ltd (Israel)     | Immunochromatography HIV1 (gp41) and HIV2 (gp36) recombinant proteins synthetic peptides                            | Antigens linked to colloidal selenium                                                      | Anti HIV antibodies HIV peptide                                                                           | 50 µL 15–60 mn            |
| INSTI HIV 1/2               | Biolytical (Canada)       | Immunofiltration HIV1 (gp41) and HIV2 (gp36) recombinant proteins                                                   | Protein A labelled with blue indigo                                                         | Protein A                                                                                                 | 50 µL 5 mn                |
| Determine Combo Ag AC HIV 1–2 | Organics Ltd (Israel)     | Immunochromatography 1/HIV1 (gp41) and HIV2 (gp36) recombinant proteins synthetic peptides 2/Avidine to capture anti p24 labelled antibodies | Antigens linked to colloidal selenium Anti HIV-1 p24 antibodies linked to biotin             | No data available                                                                                        | 50 µL 15–60 mn            |

doi:10.1371/journal.pone.0011581.t001
Mc Nemar test for paired samples was used to compare the sensitivities of the OraQuick test on OF versus FSB [16]. The same statistical test was used to compare the sensitivity of the different rapid tests on FSB, and to compare the sensitivity of these tests on either FSB or serum. Indeed, rapid tests which were falsely negative on FSB were repeated on the corresponding sera. We did not repeat all the tests on serum, assuming that tests positive on FSB would also be positive on serum.

Baseline characteristics of the patients in whom all the tests were positive were compared with those of patients with at least one negative test, using the chi-square test and Wilcoxon rank sum test in order to identify factors associated with false-negative results. A p value of <0.05 was considered to denote statistical significance. The SAS 9.1 software package (SAS Inc, Cary, NC) was used for all analyses.

Results

The HIV-infected patients were mostly men (83%) of European origin (59.8%), with HIV-1 subtype B infection (63.3%), under antiretroviral therapy (68.5%), and with plasma HIV-1 RNA <200 cp/ml (57.8%). Their median CD4 cell count was 437/mm³. Patient acceptance of this protocol was particularly high, as recruitment took place during quarterly follow-up visits by the patients’ usual doctors.

Sensitivity was 86.5% [81–90.5] with OraQuick OF, 94.5% [90.4–96.9] with OraQuick FSB, 98.5% [95.6–96.5] with Vikia, 94.9% [90.8–97.2] with Determine, 95.8% [91.6–97.9] with Determine 4G and 99% [96.3–99.7] with INSTI (p<0.0001). OraQuick was significantly less sensitive on OF than on FSB (p=0.0003). The sensitivity of OraQuick on OF was also significantly lower than the sensitivity of the tests using FSB (p=0.0002, 0.006, 0.0002, and 0.004 for Vikia, Determine, INSTI and Determine 4G, respectively). The sensitivity of OraQuick and Determine on FSB was significantly lower than that of INSTI (p=0.025 and 0.03, respectively).

Overall, 60 tests (5.2%) were falsely negative on samples from 36 patients. Among the six patients with three or more negative tests, two had recent HIV infection, and four had undetectable plasma viral load on antiretroviral therapy; one of the latter patients was infected by HIV-1 group O. The 2 seroconverter patients were infected by HIV-1 subtypes B and F, less than 2 months previously. Recent infection was confirmed by a weakly positive 4th generation EIA test and by Western blot profiles showing a typical seroconversion pattern with isolated Gag-Env weak reactivity in both subjects without Pol p31 band [17]. Western blot follow up confirmed the seroconversion in both cases. Their viral loads were 5 206 179 and 14 836 copies/ml, respectively. P24 antigen was detectable at 380 pg/ml in the plasma of the first patient but was not detectable in the other patient. All rapid tests were negative in both patients, with the exception of the INSTI test, which was weakly positive in the latter patient. No P24 antigen band was seen in the Determine 4G test in either of the patients with recent infection.

Four other patients had three or more negative rapid tests:

- Only the Vikia and INSTI tests were positive in a 34-year-old man with HIV-1 group O infection. Viral load was undetectable on HAART and his CD4 cell count was 159/mm³. When tested on serum, only OraQuick remained negative.
- Only the Vikia and INSTI rapid tests were positive (weak reactivity) in a 42-year-old Caucasian man who was diagnosed with HIV-1 B subtype infection in March 2005. His viral load was undetectable on HAART and his CD4 cell count was 675/mm³. When tested on serum, OraQuick remained negative.
- OraQuick (OF and FSB) Vikia, Determine and Determine 4G were negative in a 40-year-old Caucasian man diagnosed with HIV-1 subtype B infection in March 1999. Viral load was undetectable on HAART and his CD4 cell count was 861/mm³. When tested on serum, only OraQuick remained negative.
- The OraQuick (OF and FSB) and INSTI tests were negative in a 27-year-old woman of African origin who had been diagnosed with HIV infection (indeterminate subtype) in September 2004. Her viral load was undetectable on HAART and her CD4 cell count was 831/mm³. INSTI remained negative on serum and OraQuick was weakly positive.

Among the six patients with HIV-2 infection, two had a false-negative OraQuick test on OF but both were positive on FSB. These two patients were receiving antiretroviral therapy and their plasma viral load was undetectable in an HIV-2-specific assay. All 20 HIV-negative controls were negative in all the rapid tests. Of note, 39 (3.2%) tests were invalid, owing the absence of the control line. The Determine 4G test gave 33 invalid results (16.5%) (Table 2).

Among the 18 patients (33 tests) with at least one negative FSB test, all but six had positive results on serum (5 negative with OraQuick previously falsely negative in FSB and 1 with INSTI) (Table 3). These 6 patients with negative rapid tests on serum were the same as those with at least three negative tests on FSB (see above), i.e. the two patients with recent HIV-infection, and four patients with undetectable plasma viral load on antiretroviral

| Table 2. Sensitivity of five rapid HIV tests in 200 HIV-infected patients, using either oral fluid (OF) or finger-stick whole blood (FSB). |
|---|---|---|---|---|---|
| **Invalid test** | OraQuick OF | OraQuick FSB | Vikia FSB | Determine FSB | INSTI FSB | Determine 4G FSB |
| Negative test | 0 | 0 | 0 | 4 | 2 | 33 |
| Weakly positive test* | 10 | 6 | 1 | 1 | 4 | 7 |
| Positive test | 163 | 183 | 196 | 185 | 192 | 153 |
| Overall sensitivity % of valid tests [95% CI] | 86.5% [81–90.5] | 94.5% [90.4–96.9] | 98.5% [95.6–99.5] | 94.9% [90.8–97.2] | 99% [96.3–99.7] | 95.8% [91.6–97.9] |

Sensitivity was calculated by dividing the sum of positive and weakly positive tests by the number of valid tests. Tests without a visible control line were considered invalid.

*only a faint band was visible, but the test was considered positive.

doi:10.1371/journal.pone.0011581.t002
therapy. Assuming that the tests positive on FSB would also have been positive on serum, the sensitivities of OraQuick, Determine and Determine 4G were significantly better on serum than on FSB with 94.5% [90.4–96.9] vs 97.5% [94.2–98.9] p = 0.04, 94.9% [90.8–97.2] vs 100% [98.1–100], p = 0.004, and 93.8% [91.6–97.9] vs 100% [98–100], p = 0.02, respectively (Table 3). When the 39 tests with invalid results on FSB were repeated on serum, only four remained invalid (all with the Determine 4G).

The P24 band of the Determine 4G test was never positive on FSB, even in the patient with 380 pg P24/ml of serum. Determine 4G was also negative for P24 antigen on serum from this patient.

Only plasma HIV-1 RNA level below 200 copies/ml and elevated CD4 cell counts were significantly associated with the risk of having at least one negative test. However, the significant association (p = 0.04) with the CD4 cell count disappeared in multivariate analysis and only plasma HIV RNA, <200 cp/ml remained significantly associated with the risk of having at least one false-negative result (odds ratio: 3.67, 95% CI: 1.52–8.84, p = 0.009) (Table 4).

HIV genetic diversity in our population was high, with 36.7% of non B subtypes and a large panel of complex recombinant strains. Six patients were also infected by HIV-2 and one by HIV-1 group O. Table 5 summarizes the results according to the type and subtype. There was no significant difference in sensitivity among the different rapid tests for B or non B HIV-1 subtype infection (Fisher exact test, p>0.25).

**Table 3.** Sensitivity of five rapid HIV tests in 200 HIV-infected patients, combining the results for finger-stick whole blood and, when the latter was negative, for serum.

|                      | Oraquick FSB | Vikia FSB | Determine FSB | INSTI FSB | Determine 4G FSB |
|----------------------|-------------|-----------|---------------|-----------|-----------------|
| Positive test in serum | 6/11        | 3/3       | 10/10         | 1/2       | 7/7             |
| Overall serum sensitivity % [95% CI] | 97.5% [94.2–98.9] | 100% [98.1–100] | 100% [98.1–100] | 99.5% [97.2–99.9] | 100% [98–100] |
| P                    | 0.04        | 0.25      | 0.004         | 1         | 0.02            |

Differences in sensitivity between whole blood and serum were analyzed with the McNemar test for paired samples. doi:10.1371/journal.pone.0011581.t003

**Table 4.** Comparison of patient characteristics according to HIV screening rapid tests results on whole blood and/or oral fluid results.

|                      | All tests positive | ≥1 negative test | p-value uni-variate analysis | p-value multi- variate analysis |
|----------------------|--------------------|------------------|-------------------------------|-------------------------------|
| n = 164              |                    |                  |                               |                               |
| Median age (years)   | 41                 | 44.5             | 0.24                          |                               |
| Female (n, %)        | 28 (17%)           | 6 (16.6%)        | 1.00                          |                               |
| CDC stage C (n,%)    | 37 (22.5%)         | 11 (30.5%)       | 0.39                          |                               |
| Caucasian            | 93 (57.1%)         | 26 (72.2%)       | 0.24                          |                               |
| Sub-Saharan African  | 53 (32.5%)         | 8 (22.2%)        |                               |                               |
| Other                | 17 (10.4%)         | 2 (5.6%)         |                               |                               |
| HBV or HCV infection (n,%) | 16 (9.8%)  | 3 (8.3%)         | 1.00                          |                               |
| ARV therapy (n,%)    | 108 (65%)          | 29 (80.5%)       | 0.11                          |                               |
| Date of HIV infection ≤2002 | 96 (58.5%) | 19 (52.8%)       | 0.58                          |                               |
| Median CD4 cell count | 416                | 500              | 0.04                          | 0.11                          |
| HIV VL <200 cp/ml (n,%) | 87 (53.1%)       | 29 (80.5%)       | 0.004                         | 0.009                         |
| HIV-1 B subtype (n,%) | 106 (64.6%)       | 20 (55.6%)       | 0.34                          |                               |
| HIV-2                | 4 (2.4%)           | 2 (5.5%)         |                               |                               |
| HIV-O                | 1 (2.5%)           |                  |                               |                               |
| others               | 2 recent infection |                  |                               |                               |

doi:10.1371/journal.pone.0011581.t004

Discussion

This is the first study to compare the sensitivity of EU-approved rapid HIV screening tests, on oral fluid, capillary blood and serum. Among the 200 HIV-infected volunteers included in this study, rapid test sensitivity ranged from 86.5% [81–90.5] to 99% [96.3–99.7]. Thirty-six patients had a false-negative result in at least one of the six tests. OraQuick was the least sensitive test on both OF and whole blood and also yielded the largest number of “weakly positive” results. OraQuick sensitivity improved from 86.5% to 94.5% (p = 0.008) when FSB rather than OF was used, and to 97.5% when serum was used (p = 0.04, Table 3). On testing serum from patients with false-negative tests on FSB, only six tests remained falsely negative (OraQuick in 5 cases, INSTI in one case). These rapid tests are usually used to screen patients exposed to or suspected of being infected by HIV. In this indication, it is recommended to use two tests simultaneously to improve
In a study of 327 patients, Delaney found more false-negative results with OraQuick on OF than on whole blood (99.1% versus 99.7%) [20]. Likewise, in a study of 81 patients in South Africa, the sensitivity of OraQuick was only 96.3% on OF, compared to 100% on whole blood [21]. In a study of 139 patients, the sensitivity of OraQuick was lower on OF (97.8%, with 3 false-negatives) than on serum or plasma (100%) [22]. In these studies, all the patients with false-negative OraQuick results had undetectable viral load during this period. However, except for OraQuick, all the tests were reactive on serum from both patients. These patients had specific antibodies on Western blot (WB) and one already had undetectable P24 antigenemia, indicating that they were in the later stages of primary infection. Evaluation of rapid tests for diagnosis of recent HIV infection in healthcare settings is hindered by the difficulty of recruiting such patients, but the lack of rapid test sensitivity in this setting has already been underlined. In 2007, Stekler et al reported three cases of recent HIV infection (less than 6 months) with negative OraQuick results on whole blood [23]. In 2009, the same authors reported the limits of OraQuick rapid testing on OF and FSB in the USA [24]. Rapid testing was positive in 153 (91%) of 169 HIV-infected men who have sex with men, all of whom were positive by EIA and/or nucleic acid testing. Fourteen patients with primary infection and one profoundly immunodepressed patient were positive in a 4th generation EIA test detecting both P24 antigen and anti-HIV antibodies [24]. Such combined assays are highly sensitive, detecting less than 15 picograms of P24/µl [25]. P24 antigen detection is useful for closing the primary infection “window” period [17]. Determine 4G, the first such rapid test, needs to be made more sensitive, as none of the whole-blood samples from our 200 patients reacted with the P24 antigen line. This could be due to the relatively early stage of HIV infection and to the control of viral replication by treatment or to the African origin of many of our patients (61 cases). Similarly, Tardy et al, using serum samples from HIV-infected patients positive for P24 antigen, found that none of the 17 patients with less than 50 pg of P24 antigen per milliliter of serum was positive for P24 in the Determine 4G test, while only 4 of the 9 patients with values between 50 and 400 pg/ml were positive [26]. There is insufficiency of literature on rapid test in health care setting with recent HIV infection due to the difficulty to include such patients [23,24,27]. This lower sensitivity of rapid tests during primary HIV infection increases the risk of misdiagnosis in patients with active viral replication and a high risk of transmission, implying that these tests should be used with care, particularly on OF or whole blood, in populations with a high incidence of HIV infection, especially in primary care or emergency settings [28]. Possible explanations for this lower sensitivity of rapid tests include weaker antibody affinity due to hemolysis, dilution in whole blood, the short migration or filtration time for antigen-antibody binding, and reaction at room temperature instead of 37°C as in EIA tests [29].

HIV antigenic diversity has been implicated in poor antibody detection by rapid tests, particularly in case of variant or primary infection [8,27]. In our study, the difference in the frequency of false-negative results for subtype B and non B HIV-1 group M was not statistically significant. HIV screening tests use synthetic antigens based on sequences of HIV-1 subtype B viruses that circulate in western countries. In case of HIV-1 non B or highly

---

### Table 5. Sensitivity of rapid test detection according to the HIV genotype.

| HIV-1 Subtype B | N 199* | Positive (%) | Negative | Invalid |
|-----------------|--------|--------------|----------|---------|
| OraQuick OF     | 111 (88) | 15 (7)        | 7         | -       |
| OraQuick FSB    | 119 (94) | 2 (5)         | 7         | -       |
| Vikia FSB       | 124 (97) | 1 (5)         | -         | -       |
| Determine FSB   | 118 (94) |              | -         | -       |
| Insti FSB       | 123 (97) |              | -         | -       |
| Determine 4G FSB| 96 (76)  |              | -         | -       |

| HIV-1 Subtype Non B** | N 58 | Positive (%) | Negative | Invalid |
|-----------------------|------|--------------|----------|---------|
| OraQuick OF           | 51 (87) | 7 (3)        | 3         | 2 (5)   |
| OraQuick FSB          | 55 (94) | 6 (6)        | -         | 2 (5)   |
| Vikia FSB             | 57 (98) | -            | -         | -       |
| Determine FSB         | 52 (89) | -            | -         | -       |
| Insti FSB             | 58 (100) | -            | -         | -       |
| Determine 4G FSB      | 49 (84)  | -            | -         | -       |

| HIV-2 | N 6 | Positive (%) | Negative | Invalid |
|-------|-----|--------------|----------|---------|
| OraQuick OF | 4 (6) | 2 (2) | - | - |
| OraQuick FSB | 6 (6) | 1 (1) | - | - |
| Vikia FSB | - | - | - | - |
| Determine FSB | - | - | - | - |
| Insti FSB | - | - | - | - |
| Determine 4G FSB | - | - | - | - |

| HIV-2 not typable | N 9 | Positive (%) | Negative | Invalid |
|-------------------|-----|--------------|----------|---------|
| OraQuick OF       | 7 (8) | 2 (2) | - | - |
| OraQuick FSB      | 8 (9) | 1 (1) | - | - |
| Vikia FSB         | 9 (9) | - | - | - |
| Determine FSB     | 8 (8) | - | - | - |
| Insti FSB         | - | - | - | - |
| Determine 4G FSB  | - | - | - | - |

*Failure from PCR, serotyping insufficient volume in one sample;
**HIV-1 Subtype non B: A (3); D (2); F (2); J (1); O (1); CRF01 (3); CRF02 (17); CRF06 (1); CRF19 (1); Recombinant B/CRF02 (1); Complex recombinant (2); Serotyped as non B (24).
Fischer exact test, p = 0.25.

doi:10.1371/journal.pone.0011581.t005
References

1. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, et al. (2009) Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clin Infect Dis 49: 1570–1578.
2. Hamers FF, Phillips AN (2008) Diagnosed and undiagnosed HIV infected populations in Europe. HIV Med 9 (Suppl 2): 6–12.
3. Delerue C, Ouni L, Lawrens-Cances V, Marchou L, Lang T, et al. (2006) High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDs 20: 838–847.
4. Brainstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817–824.
5. Kigozi I, Dobkin L, Martin JN, Geng EH, Muyindike W, et al. (2009) Late-Diagnosis of HIV-1-infected Patients at Presentation to an HIV Clinic in the Era of Free Antiretroviral Therapy in Sub-Saharan Africa. J AIDS 52: 209–219.
6. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, et al. (2006) Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 55 (RR-14): 1–17.
7. Spielberg F, Kabeya CM, Ryder RW (1989) Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus. Lancet 333: 580–584.
8. Makuiwa M, Soupaître S, Niangou MT, Rouquet P, Apertii C, et al. (2002) Reliability of rapid diagnostic tests for HIV variant infection. J Virol Methods 103: 183–190.
9. Directive 90/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Commission Decision of 3 February 2009 amending. Available: http://eur-lex.europa.eu/fr/index.htm.
10. Decision 2002/364/EC on common technical specifications for in vitro-diagnostic medical devices. 2009/108/EC Available: http://eur-lex.europa.eu/en/LexUriServ/LexUriServ.do?uri=OJ:L:2002:131:0017:0030.
11. Council national du sida. Rapport sur l'évolution du dispositif de dépistage de l'infection par le VIH en France. Suivi de recommandations, adopté lors de la séance plénière du 16 novembre 2006 sur proposition de la commission "Dépistage". Available: http://www.cssante.fr/spip.php?article263.
12. Simon F, Sosquèire S, Damond F, Kfnwha A, Makwca M, et al. (2001) Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses 17: 957–952.
13. von Sydow M, Gaines H, Somnerberg A, Forsgren M, Petrinova PO, et al. (1988) Antigen detection in primary HIV infection. Br Med J 296: 238–240.
14. Ehleman SH, Khaki L, Laeyendecker O, Prowar-Manning E, Johnson-Lewis L, et al. (2009) Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr 52: 121–124.
15. Leung DH, Wang YG, Zhu M (2009) Efficient parameter estimation in longitudinal data analysis using a hybrid GEE method. Biostatistics 10: 436–445.
16. Smith W, Solow AR (1996) An Exact McNemar Test For Paired Binary Markov Chains. Biometrics 52: 1063–1070.
17. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871–1879.
18. Joint United Nations Programme on HIV/AIDS (UNAIDS) – WHO (1997) Revised recommendations for the selection and use of HIV antibody tests. Weekly epidemiological record 72: 81–88.
19. Technical Expert Panel Review of CDC HIV Counseling, Testing, and Referral Guidelines. (2001) Recommendations an Reports Revised Guidelines for HIV Counseling, Testing and Referral. MMWR 50(RR19): 1–58.
20. Delaney KP, Branson BM, Uniyal A, Kerndt PR, Keenan PA, et al. (2006) Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 20: 1655–1660.
21. Scott LE, Noble LD, Langeveld M,Jeutsch U, Francois Venter WD, Stevens W (2009) Can oral fluid testing be used to replace blood-based HIV rapid testing to improve access to diagnosis in South Africa? J Acquir Immune Defic Syndr 51: 646–648.
22. Holguin A, Gutierrez M, Portocarrero N, Rivas P, Baquero M (2009) Performance of OraQuick Advanced Rapid HIV-1/2 Antibody Test for detection of antibodies in oral fluid and serum/plasma in HIV-1+ subjects carrying different HIV-1 subtypes and recombinant variants. J Clin Virol 45: 150–152.
23. Stekler JD, Wood RW, Swenson PD, Golden M (2007) Negative rapid HIV antibody testing during early HIV infection. Ann Intern Med 147: 147–148.
24. Stekler JD, Swenson PD, Groombo RW, Dragovan J, Thomas KK, et al. (2009) HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis 49: 444–445.
25. Ly TD, Elbel A, Faucher V, Fihman V, Lapereche S (2007) Could the new HIV combined P24 antigen and antibody assays replace P24 antigen specific assays? J Virol Methods, 143: 86–94.
26. Tardy JC (2009) Test Rapide VIH de 4e génération. Journée Nationale d’Infectiologie Lyon. Available: http://www.infectiologie.com/site/medias/JNI/JN09/VIH/TARDY-depist.JN09.
27. Lalorgerie E, Boucher B, Ly TD, Maisonneuve L, Izopet J, et al. (2010) Sensitivity of 3 CE (European Community)-approved rapid disposable tests for anti-HIV antibody detection during and after seroconversion. J Virol Methods 165: 105–107.
28. Everett DB, Sables K, Changhalucha J, Vallety A, Watson-Jones D, et al. (2009) Suitability of Sample Human Immunodeficiency Virus Rapid Tests in Clinical Trials in Community-Based Clinic Settings. J Clin Microbiol 47: 1058–1062.
29. Schochetman G, George J (1992) Serologic tests for the detection of human immunodeficiency virus infection. In AIDS Testing Methodology and Management Issues, Springer-Verlag, New York.
30. Apetrei C, Oustart-Ajak S, Droscamps D, Damond F, Saragosti S, et al. (1996) Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 10: 57–60.
31. Gaither-Carvajal A, Mesmin-Poho S, Begin J, Lerner V, Huxaux JM, et al. (2008) Unequal detection of HIV type 1 group O infection by simple rapid tests. Clin Infect Dis 46: 1936–1937.
32. Barin F, Cazein F, Lot F, Pimentel J, Brunet S, et al. (2007) Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 21: 2351–53.
33. Wesolowski LG, MacKellar DA, Facente SN, Dowling T, Ethridge SF, et al. (2006) Post-marketing surveillance of OraQuick whole blood and oral fluid rapid HIV testing. AIDS 20: 1661–1666.
34. Facente SN, Dowling T, Vittinghoff E, Sykes DL, Colfax GN (2009) False positive rate of rapid oral fluid HIV tests increases as kits near expiration date. PLoS One 4: e8217.
35. Wesolowski LG, Ethridge SF, Martin EG, Cadott EM, MacKellar DA (2009) Rapid human immunodeficiency virus test quality assurance practices and outcomes among testing sites affiliated with 17 public health departments. J Clin Microbiol 47: 3333–3335.
36. Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M, et al. (2009) Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One 4: e7702.